Structural Investigation of Viral Surface Glycoproteins
- Funded by Wellcome Trust
- Total publications:2 publications
Grant number: 228344
Grant search
Key facts
Disease
Rift Valley feverStart & end year
20232026Funder
Wellcome TrustPrincipal Investigator
Mr. Miles GrahamResearch Location
United KingdomLead Research Institution
University of OxfordResearch Priority Alignment
N/A
Research Category
Vaccines research, development and implementation
Research Subcategory
Characterisation of vaccine-induced immunity
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Unspecified
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified
Abstract
Viral surface glycoproteins are essential to viral replication cycles, mediating viral entry and escape. However, their surface exposure renders them key immunological targets and the centre of most vaccine designs. A comprehensive structural understanding of surface viral glycoproteins is therefore needed to understand their recognition by broadly neutralising antibodies (bnAbs) which are ideally produced in response to vaccination. This research will engage two high-priority viral pathogens, namely Human immunodeficiency virus (HIV) and Rift Valley Fever Virus (RVFV). The aims of this work will be two-fold. For HIV-1 there remain key questions surrounding its glycoprotein biology which have significant implications for future vaccine design. We will investigate these questions by cryo-EM of native HIV-1 Envelope (Env) glycoprotein. Secondly, RVFV vaccines are under trial and remain to be studied from a structural mechanistic standpoint. Therefore, I will seek to understand how the nChAdOx1 RVF vaccine is working at the molecular level to elicit protective antibody responses in patients.
Publicationslinked via Europe PMC
Last Updated:an hour ago
View all publications at Europe PMC